Navigation Links
TPI Reports Fiscal Year 2013 Financial Results
Date:9/27/2013

other uncertainties detailed in the Company's filings with the Securities and Exchange Commission.

For more information, please contact:

Investors Contact: ir@tpi.asia
Web: http://www.tianyinpharma.com
Tel: +86-28-8551-6696 (Chengdu, China)
+86 134-36-550011 (China)

Address:

23rd Floor Unionsun Yangkuo Plaza
No. 2, Block 3, South Renmin Road
Chengdu, 610041
ChinaTIANYIN PHARMACEUTICAL CO., INC.Consolidated Statements of OperationsFor the Years Ended June 30,20132012Sales$67,500,476$69,605,758Cost of sales41,496,81245,274,326Gross profit26,003,66424,331,432Operating expensesSelling expenses11,442,66410,672,817General and administrative expenses4,351,5924,255,528Research and development894,995860,081Total operating expenses16,689,25115,788,426Income from operations9,314,4138,543,006Other income (expenses):Interest income162,563209,037Interest expense(437,897)(331,334)Other income-189,268Total other income (expenses)(275,334)66,971Income before provision for income taxes9,039,0798,609,977Provision for income taxes2,423,9062,368,059Net income6,615,1736,241,918Less: Net loss attributable to noncontrolling interest(56,978)(116,772)Net income attributable to Tianyin Pharmaceutical Co., Inc.6,672,1516,358,690Basic earnings per share$0.23$0.22Diluted earnings per share$0.23$0.22Weighted average number of common shares outstanding:Basic29,341,69529,308,442Diluted29,341,69529,308,442 TIANYIN PHARMACEUTICAL CO., INC.Consolidated Statements of Comprehensive IncomeFor the Years Ended June 30,20132012Net income$6,615,173$6,241,918Other comprehensive incomeForeign currency translation adjustment2,083,0612,065,066Total other comprehensive income2,083,0612,065,066Total Comprehensive income8,698,2348,306,984Less: Comprehensive income attributable to the noncontrolling interest(51,749)(74,933)Comprehensive income attributable toTianyin Pharmaceutical Co., In
'/>"/>

SOURCE Tianyin Pharmaceutical Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related medicine technology :

1. Isis Reports Phase 2 Data on ISIS-APOCIII Rx Showing Substantial Reductions of Triglycerides and Apoc-III in Patients with Familial Chylomicronemia
2. Omeros Reports Initiation of Phase 2 Clinical Trial with OMS824
3. Isis Reports Follow-Up Data From ISIS-SMN Rx Phase 1 Study In Children With Spinal Muscular Atrophy
4. InspireMD Reports Fourth Quarter and Fiscal Year 2013 Results
5. Apollo Medical Holdings Reports Record Fiscal 2014 Second Quarter Results
6. Cyberonics Reports Inducement Equity Award Under NASDAQ Listing Rule 5635(c)(4)
7. Genocea Reports Positive Initial Phase 1/2a Results for GEN-003, its Pioneering Therapeutic Vaccine Candidate for the Treatment of Herpes Simplex Virus-2 (HSV-2), at ICAAC 2013
8. Omeros Reports Additional Positive Results from OMS824 Program
9. S&P Capital IQ Initiates Coverage on Epigenomics AG in Standard & Poors Factual Stock Reports
10. CorMedix Reports Receipt of European Patent Office Decision to Allow Prosl Patent to Proceed in European Union
11. Market Research Reports: Biologics, Biosimilars, Bioseparation Systems for Biopharmaceutical Markets
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/6/2015)... 2015  OncoSec Medical Inc. ("OncoSec") (NASDAQ: ONCS ... announced the appointment of Joann V. Lofgren ... Market Development, effective July 6, 2015. In this role, ... executing on the company,s market and product development strategy ... to welcome Joann to the OncoSec team and have ...
(Date:7/5/2015)... TOKYO , July 6, 2015 ... first international symposium on Medical-Engineering Collaboration "Medicine ... on July 10, 2015 in Tokyo, ... or its medical applied research will present their ... technology and a new industry produced with 8K ...
(Date:7/4/2015)... Adding SIR-Spheres® Y-90 resin ... metastatic colorectal cancer in the liver (mCRC) further ... Patients with unresectable metastatic colorectal cancer (mCRC) that ... greatest improvement in Progression-Free Survival (PFS) in the ... microspheres to a current first-line chemotherapy regimen, according ...
Breaking Medicine Technology:OncoSec Medical Appoints Joann V. Lofgren as Vice President of Market Development 2OncoSec Medical Appoints Joann V. Lofgren as Vice President of Market Development 3Nihon University to Host International Symposium on Medical-Engineering Collaboration 2Nihon University to Host International Symposium on Medical-Engineering Collaboration 3New SIRFLOX Study Data Presented at World Congress of Gastrointestinal Cancer 2New SIRFLOX Study Data Presented at World Congress of Gastrointestinal Cancer 3New SIRFLOX Study Data Presented at World Congress of Gastrointestinal Cancer 4
... MATEO, Calif., Feb. 28, 2011 Nile Therapeutics, Inc. ... the development of novel therapeutics for heart failure patients, ... MDT ) on the clinical development of ... failure and renal disease applications. "We are ...
... 2011 Hotspur Technologies announced today that Dr. ... clinical use of its Keeper™ Embolectomy Catheter.  The ... within arteries, while also incorporating the capability of ... The Keeper Catheter combines a compliant ...
Cached Medicine Technology:Nile Therapeutics to Collaborate with Medtronic on Clinical Development of Cenderitide for Heart Failure and Renal Disease 2Nile Therapeutics to Collaborate with Medtronic on Clinical Development of Cenderitide for Heart Failure and Renal Disease 3Hotspur's Keeper Embolectomy Catheter Deployed for First Time 2
(Date:7/6/2015)... ... July 06, 2015 , ... ... stages of drug discovery. iPSCs are generated from adult cells, such as blood ... cell type in the human body. , iPSC-derived cardiomyocytes have ...
(Date:7/6/2015)... ... 2015 , ... “ TapGlance ” was featured on NewsWatch as part of ... the market for iOS, Android, and Windows. Joe Toohey, the host of AppWatch and ... app helps users visualize what rooms will look like before they even start renovating.. ...
(Date:7/6/2015)... ... ... report titled “ Female Hair Loss Needs to be Talked About, Shed Stigma, Experts Say,” ... U.S. will suffer from thinning hair or hair loss . For these 30 million women, ... queen, who was interviewed for the report began losing her hair at age 11 due to ...
(Date:7/6/2015)... York, NY (PRWEB) , ... July 06, 2015 ... ... their health care from nurses or midwives, yet there is a large gap ... nursing and midwifery research required to improve health outcomes and reduce unnecessary or ...
(Date:7/6/2015)... ... 2015 , ... Olive Fertility Centre is proud to announce that Olive medical ... behalf of the department of Family Practice. , “This award is a real honour,” ... The technology is changing so rapidly and we are also developing new models of ...
Breaking Medicine News(10 mins):Health News:Cellular Dynamics’ Webinar Underscores the Value of Using Human iPSC-derived Cardiomyocytes for Investigative in vitro Drug Toxicology 2Health News:Cellular Dynamics’ Webinar Underscores the Value of Using Human iPSC-derived Cardiomyocytes for Investigative in vitro Drug Toxicology 3Health News:Cellular Dynamics’ Webinar Underscores the Value of Using Human iPSC-derived Cardiomyocytes for Investigative in vitro Drug Toxicology 4Health News:Create a Space with TapGlance, a Revolutionary Interior Design Application 2Health News:The Stigma of Female Hair Loss and Hair Restoration Solutions 2Health News:Columbia Nursing Nairobi Summit: Setting a Clinical Research Agenda for Africa 2Health News:Olive Fertility Centre Physician Honoured for Teaching 2
... Heart surgeons are getting ready for the first heart valve ... ,The operation is scheduled for Tuesday and will be performed ... is termed as percutaneous aortic valve replacement. This technique called ... , The novelty of this surgery is that it ...
... A new study conducted by New Agricultural Research Service ... varying thickening capacity //and this information is expected to ... ,Peanut flour is obtained after partial extraction of oil ... products, nutrition bars and snacks, marinades, sauces and dressings ...
... Minister Girija Prasad Koirala's sister-in-law and Nepal's most ... problems and other infections in hospital, media reports ... Shahid Gangalal National Heart Centre, the same hospital ... treatment and observation for nearly a week last ...
... a healthcare presentation into Japanese for an American client who ... a task not many can undertake. //And all this from ... Matheson, is proving that it is possible. Specialising in providing ... by delivering on the dot and raking in millions of ...
... hazards and a frenetic job pace increases the likelihood ... new systematic review suggests.// ,Work setting also ... of injury, with food service and construction industry jobs ... group. ,“These studies provide sufficient evidence that ...
... most commonly prescribed antidepressants are similar in effectiveness to ... side effects, according to an analysis// released today by ... ,The findings, based on a review of nearly 300 ... in 10 adult patients get some relief from the ...
Cached Medicine News:Health News:Nepal's Most Influential Woman 'Critically' Ill 2Health News:Cashing in on IT for Healthcare 2Health News:Workplace Pressures, Hazards Raise Risk of Job Injuries in Youths 2Health News:Workplace Pressures, Hazards Raise Risk of Job Injuries in Youths 3Health News:Newer Class of Antidepressants Similar in Effectiveness, Side Effects Differ 2Health News:Newer Class of Antidepressants Similar in Effectiveness, Side Effects Differ 3
Round solid 15 mm wide lower plate. Open upper plate with inside diameter 12 mm. Serrated handle with locking thumb screw and polished finish....
Round solid 10 mm wide lower plate. Open upper plate with inside diameter 8 mm. Serrated handle with locking thumb screw and polished finish. Most popular size or model....
The popular E2002 Utrata Capsulorhexis Forceps with fine angled sharp tips. Angled 12 mm shafts with an iris stop. Flat handle with dull finish....
Fine angled tips ideal for grasping delicate capsule. Angled 12 mm shafts with iris stop allows ease of movement in the anterior chamber. Flat handle with dull finish. Manufactured in titanium....
Medicine Products: